Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease
about
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's DiseaseMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseThe kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's diseaseTryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolitesTargeted Deletion of Kynurenine 3-Monooxygenase in Mice: A NEW TOOL FOR STUDYING KYNURENINE PATHWAY METABOLISM IN PERIPHERY AND BRAINModel of tryptophan metabolism, readily scalable using tissue-specific gene expression data.Modeling Huntington disease in yeast: perspectives and future directions.Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosusPrognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.A systems-level "misunderstanding": the plasma metabolome in Huntington's diseaseTryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation.The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases.Heterogeneity of CNS myeloid cells and their roles in neurodegeneration.Protein oxidation in Huntington disease.Harnessing the power of yeast to unravel the molecular basis of neurodegeneration.The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target.Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).Kynurenine Monooxygenase (KMO) Inhibitors for the Treatment of Acute Pancreatitis and Neurodegenerative Disorders.Yeast models for amyloid disease.Drosophila eye color mutants as therapeutic tools for Huntington disease.The role of tryptophan metabolism in postpartum depression.Studying Huntington's Disease in Yeast: From Mechanisms to Pharmacological Approaches
P2860
Q26781849-B469FCDF-B4E2-463D-B4B9-D38F908BD226Q27005950-F9612BB8-4A64-44E8-875B-919332C59A4AQ27011417-4DFF5FF9-E508-4356-B939-0BD3180D19C1Q28239367-B42A801A-3C63-4B5A-9B16-15F9E8F4F474Q28834131-125B23A4-3DEB-4978-8AE3-61A2254BEC2BQ29306917-20643AAF-CD03-4AF9-B30C-571443317085Q30678210-D34224EE-B699-4B57-8D75-9DF9B546FDFEQ33575494-39DFA9EF-E35C-4222-83DB-2019065F2A18Q35512674-527681E1-9BC1-40D0-9C09-CD307380E08EQ35775787-ABF877C9-061C-48B6-A3A5-E368E0004B19Q35935105-F37D5151-9010-4622-B636-C54DB54C69BFQ37013795-31AA5473-1D10-4235-968F-56371B3A0DECQ37351984-DB3F58D2-DDD0-4E69-8E09-C864703464D0Q37623378-44DE88FF-7BF1-4BE4-9561-F1E1128A93D6Q37939514-9E5AC4AC-D879-4042-944B-E1C6E2CCDD46Q37999718-D0B2C66E-E834-48C2-BD9B-3EF49CDDD85FQ38100231-2292AFED-5178-4D20-B44D-22B66D1795D4Q38103448-93FC7E6F-066A-4F49-9227-AD41FE6D299EQ38253558-0F195D5B-0B69-4CB6-BEF6-8F1A4D933E66Q39004244-8CE538AA-1B65-47C7-B1B1-A044CED869F3Q39149450-8080B387-CDFB-49A1-8EF1-61BAE647C874Q43242871-4424C893-0E1E-4E44-B564-5C6276B9D755Q43452372-037DCC02-933E-4252-A730-8FA12A97BBA8Q45288816-09ECF2DD-D42A-43FB-A1EE-E03CF60E18A5Q47201558-6E453C87-F883-4356-820D-D7915543D163Q58764761-B247444A-1095-4A10-91E5-54762E139DE4
P2860
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@ast
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@en
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@nl
type
label
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@ast
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@en
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@nl
prefLabel
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@ast
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@en
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@nl
P2093
P1476
Targeting kynurenine 3-monooxy ...... herapy in Huntington's disease
@en
P2093
Flaviano Giorgini
Mathuravani A Thevandavakkam
Paul J Muchowski
Robert Schwarcz
P304
P356
10.2174/187152710793237430
P407
P577
2010-12-01T00:00:00Z